ConductScience.org, home

Paper41384153

Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.

Petrakis V and 6 others. Infez Med, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece. Papers, record 41384153. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41384153

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.
PubMed
Journal
Infez Med
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-12-14
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Petrakis VVasileios
2Rafailidis PPetros
3Panopoulou MMaria
4Konstantinidis TTheocharis
5Babaka NNikoleta
6Papazoglou DDimitrios
7Panagopoulos PPeriklis

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139612160Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).Infect Dis Ther2025https://conductscience.org/library/papers/39612160PubMed
232094127
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32094127PubMed
336482958Antibiotic therapy for pan-drug-resistant infections.Infez Med2022https://conductscience.org/library/papers/36482958PubMed
426596941Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/26596941PubMed
534082265Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.Diagn Microbiol Infect Dis2021https://conductscience.org/library/papers/34082265PubMed
631430370Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance.J Antimicrob Chemother2019https://conductscience.org/library/papers/31430370PubMed
740858146Repopulate, not just decolonise-a microbial ecological strategy against multidrug resistance in intensive care units.Lancet Microbe2025https://conductscience.org/library/papers/40858146PubMed
832050434Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales.Antibiotics (Basel)2020https://conductscience.org/library/papers/32050434PubMed
935136967Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.Clin Infect Dis2022https://conductscience.org/library/papers/35136967PubMed
101329641Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1329641PubMed
1132060929Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.Pharmacotherapy2020https://conductscience.org/library/papers/32060929PubMed
1240212030Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.Open Forum Infect Dis2025https://conductscience.org/library/papers/40212030PubMed
1334901302Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.Open Forum Infect Dis2021https://conductscience.org/library/papers/34901302PubMed
1432514525In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.J Antimicrob Chemother2020https://conductscience.org/library/papers/32514525PubMed
1533058795
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis2021https://conductscience.org/library/papers/33058795PubMed
1635065702Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.Lancet2022https://conductscience.org/library/papers/35065702PubMed
1735146349Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites.Infez Med2021https://conductscience.org/library/papers/35146349PubMed
1835727059New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35727059PubMed
1929230684Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs2018https://conductscience.org/library/papers/29230684PubMed
2031740559Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31740559PubMed

See all 39 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41384153

GET https://conductscience.org/api/papers/v1/41384153/references?page=2